Watch the interview with Idogen's vd Anders Karlsson below.
BioStock Studio: Idogen's CEO comments on the issue outcome and the next important steps
On Monday, Idogen presented the outcome of the rights issue, which provides the company with financial resources to start the clinical phase I/IIa study with the cell therapy IDO 8 in patients with hemophilia A. Idogen's CEO Anders Karlsson visited BioStock's studio to tell more about the issue outcome, what the capital contribution is intended to be used for, and important events in the near future.